Pro­QR spins out a new RNA biotech fo­cused on CNS dis­eases

The Dutch biotech Pro­QR $PRQR is spin­ning out a new biotech called Amy­lon which will pur­sue a pipeline of drugs in the CNS space.

Amy­lon is get­ting start­ed with a pro­gram on be­ta amy­loid re­lat­ed dis­or­ders, fo­cus­ing on RNA-based treat­ments for a rare ge­net­ic dis­ease called Hered­i­tary Cere­bral He­m­or­rhage with Amy­loi­do­sis of the Dutch type. Pro­QR vet and CNS ex­pert Thomas de Vlaam is tak­ing the helm as found­ing CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER